PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference176 articles.
1. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners;Wong;Ann Pharmacother,2011
2. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer;Vogel;J Clin Oncol,2002
3. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition;Force;Nat Rev Cancer,2007
4. Cardiotoxicity of tyrosine-kinase–targeting drugs;Garcia-Alvarez;Cardiovasc Hematol Agents Med Chem,2010
5. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes;Force;Nat Rev Drug Discov,2011
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Involvement of protein kinases associated signal transduction mechanisms in cardiac diseases;Exploration of Medicine;2023-12-08
2. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation;Hypertension;2023-04
3. PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model;Frontiers in Cardiovascular Medicine;2022-08-03
4. Cardiovascular toxicity of PI3Kα inhibitors;Clinical Science;2020-10
5. PI3K inhibitors in thrombosis and cardiovascular disease;Clinical and Translational Medicine;2020-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3